BTK and B-cell chronic lymphocytic leukemia: Various treatment regimens for R/R CLL were included, primarily focusing on novel agents, such as BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib), PI3K inhibitors (idelalisib, duvelisib), and BCL-2 inhibitors (venetoclax).